Medicines
Discover all available medicines and treatments
Discover all available medicines and treatments
Brand: Nesina, Vipidia, SymlinPen 120, SymlinPen 60
Alogliptin is an oral anti-diabetic drug in the dipeptidyl peptidase-4 (DPP-4) inhibitor class used for the treatment of type 2 diabetes. It works by increasing the levels of incretin hormones, which help regulate blood sugar levels after meals by stimulating insulin release and decreasing glucagon secretion.
For the treatment of type 2 diabetes mellitus.
Outcome:
Increased risk of hypoglycemia
Mechanism:
Additive hypoglycemic effects.
Outcome:
Increased risk of hypoglycemia
Mechanism:
Alcohol can enhance the blood-sugar-lowering effects of alogliptin.
Outcome:
Increased digoxin levels
Mechanism:
Alogliptin may slightly increase digoxin levels.
Most likely new formulation: extended-release formulation (Year 2026, 70% confidence)
Based on current usage trends and clinical trial data, alogliptin has a low likelihood (<5%) of receiving a black box warning in the next 5 years.
Antidiabetic, DPP-4 Inhibitor
Pyrimidinediamine